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Abstract
Background—Physician communication about human papillomavirus (HPV) vaccine is a key 
determinant of uptake. To support physician communication, we sought to identify messages that 
would motivate HPV vaccination.
Methods—In 2014–2015, we surveyed national samples of parents of adolescents ages 11–17 
(n=1,504) and primary care physicians (n=776). Parents read motivational messages, selected from 
nine longer messages developed by the Centers for Disease Control and Prevention and six brief 
messages developed by the study team. Parents indicated whether each message would persuade 
them to get HPV vaccine for their adolescents. Physicians read the brief messages and indicated 
whether they would use them to persuade parents to get HPV vaccine for 11- to 12-year-old 
children.
Results—The highest proportion of parents (65%) and physicians (69%) found this brief 
message to be persuasive: “I strongly believe in the importance of this cancer-preventing vaccine 
for [child’s name].” Parents disinclined to vaccinate were most receptive to messages with 
information about HPV infection being common, cancers caused by HPV, and HPV vaccine 
effectiveness. Parents’ endorsement did not vary by race/ethnicity, education, child age, or child 
sex (all p > .05).
Conclusion—Our national surveys of parents and physicians identified messages that could 
motivate HPV vaccination, even among parents disinclined to vaccinate their children. The lack of 
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difference across demographic subgroups in parental endorsement may suggest that these 
messages can be used across demographic subgroups.
Impact—Our findings support physicians’ use of these messages with parents to help motivate 
uptake of this important cancer-preventing vaccine.
Keywords
adolescent health; cancer; health communication; healthcare providers; human papillomavirus 
vaccines
INTRODUCTION
Low uptake of human papillomavirus (HPV) vaccine is a serious public health problem that 
is thwarting progress in cancer prevention (1). Each year, an estimated 21,300 cancers in the 
United States (US) are attributable to HPV types 16 and 18 (2). These types are preventable 
through vaccination, yet only 40% of females and 22% of males ages 13–17 have received 
all three doses in the vaccine series (3). This low HPV vaccination coverage is despite 
national guidelines for routine administration (4, 5) and relatively high levels of coverage for 
other adolescent vaccines (6). Missed clinical opportunities for concomitant vaccination, 
defined as clinical visits at which a child received another vaccine but not HPV vaccine, are 
an important reason HPV vaccine initiation is not higher (7).
Healthcare provider recommendations are uniquely persuasive in motivating HPV 
vaccination. However, many physicians offer weak (8) or late recommendations (9), if they 
offer a recommendation at all. Physicians’ HPV vaccine recommendations can be 
inconsistent, with many physicians selectively recommending the vaccine to patients they 
perceive are at higher risk for infection rather than all patients (9). This practice is especially 
worrisome as receiving a physician recommendation is a robust predictor of HPV vaccine 
uptake (10–15). Given the central role physicians’ recommendations play in vaccine uptake, 
low-quality or absent physician communication about HPV vaccine undermines the 
vaccine’s tremendous potential to prevent anogenital cancers.
Recognizing the need for improved physician communication about HPV vaccination, the 
Centers for Disease Control and Prevention (CDC) developed and widely disseminated 
resources for healthcare providers through the national “You Are the Key” campaign (16). 
To help strengthen physicians’ communication, CDC offers nine messages physicians could 
use to recommend HPV vaccine to parents (6, 17). These messages were designed to address 
common parental barriers to HPV vaccination (e.g., vaccine safety, efficacy, necessity) and 
resulted from several rounds of testing with parents and physicians. Beginning with a larger 
pool of messages, CDC surveyed mothers to assess their perceptions of messages that would 
help them make the decision to get their children vaccinated. CDC then interviewed 
pediatricians to assess their understanding and usability of the messages, and conducted 
focus groups with parents to refine the messages (J. Roark, MPH, written communication, 
June 2016). However, parents’ perceptions of these messages remain unknown in the 
absence of published evaluation data. Moreover, at an average length of 52 words, these 
messages are fairly long, which may make them challenging to remember and thus deter 
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physicians’ use. Our study sought to identify messages physicians would use to recommend 
HPV vaccine and that would motivate parental acceptance. The study team also developed 
shorter messages and examined whether they were as effective as the longer CDC-developed 
messages.
MATERIALS AND METHODS
Participants and procedures
We conducted two national, online surveys of parents and physicians in the US who were 
members of standing panels maintained by a survey research company (18, 19). Parents 
were part of a panel of about 55,000 adults identified through a probability-based sampling 
of addresses from the US Postal Service’s Delivery Sequence File. This sample frame covers 
about 97% of US households. The survey research company recruited its physician panelists 
through lists compiled by the American Medical Association (20). The University of North 
Carolina Institutional Review Board approved both study protocols. We described the 
participants, procedures, and survey instruments previously (9, 21, 22) and summarize them 
here briefly.
Parent survey—Parents completed our online survey between November 2014 and 
January 2015 (22). Eligible respondents were parents of an 11–17 year old child who lived 
in the household at least half of the time. For parents who had more than one child in this 
age range, the survey asked parents to respond with regard to the child who had the most 
recent birthday. This selection method is quick, easy, and relatively non-invasive for 
participants (23), compared to a potentially more burdensome enumeration approach in 
which we obtain an identifier and request responses for every eligible child. Parents 
provided a name or nickname for the referent child, which was used in item stems 
throughout the survey. To support inclusion of lower-income respondents, the survey 
company provided a computer and free internet access to panel members without these 
resources for the duration of their participation in the survey panel (19). Parents who already 
had a computer and internet access received points for completing the survey, which could 
be redeemed for cash, products, or sweepstakes entries.
The survey company emailed invitations to 2,845 randomly selected parents. Of those, 1,760 
accessed the survey site, provided informed consent, and completed an eligibility screener. A 
total of 1,518 parents met eligibility criteria and completed the survey. After excluding 14 
parents who had incomplete data, the final analytic sample included 1,504 parents. We 
estimated that 13.75% of our total sample was not eligible for the survey, resulting in 2,454 
eligible parents. Using American Association for Public Opinion Research (AAPOR) 
definition 5 (24), the overall response rate was 61% (1,504/2,454).
Physician survey—Physicians completed our online survey between April and June 2014 
(9, 21). Eligible respondents were pediatricians and family physicians providing preventive 
care, including vaccinations, to patients ages 11–12. We were particularly interested in 
patients in this age group because they represent the target ages for routine HPV vaccination 
(2). The survey company emailed invitations to all 2,368 panel members with pediatric or 
family medicine specialties, and 1,022 (43%) clicked on the link provided to access the 
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survey site. Of these, 776 (76%) met eligibility criteria and completed the survey. The survey 
company was unable to provide the information required to calculate a response rate using 
AAPOR definitions (24). Although data on the percentage of ineligible respondents were 
unavailable, overall, 33% of physicians in the panel completed the survey. Physicians 
received $25–45 for participating, with higher incentives used to encourage participation 
later in the fielding process.
Motivational messages
The brief and longer motivational messages and their sources appear in Supplementary Table 
S1. In consultation with pediatricians, family physicians, and other experts on HPV 
vaccination, the study team developed six brief messages (defined as 25 words or fewer; 
messages B1-B6) designed to motivate HPV vaccination. Nine longer messages (defined as 
26 words or longer; messages L1-L9) came from materials that the CDC developed to aid 
physician communication with parents and adolescents about HPV vaccination (6, 17). 
Although relatively little is known about the relationship between health-related print 
literacy and health-related oral literacy, the cognitive processes necessary to understand 
information presented orally and in writing are closely connected (25). Thus, we calculated 
message readability using five standard approaches (Flesch-Kincaid Grade Level, Gunning-
Fog Score, Coleman-Liau Index, SMOG Index, Automated Readability Index) and 
calculated an average readability grade level for each message; grade 8 or lower is a 
minimum standard for readability for patient communication materials, and grade 6 or lower 
is desirable (26). On average, the brief messages were 17 words long and the reading grade 
level was 6.3 (Supplementary Table S1). The longer messages averaged 52 words and a 
reading grade level of 9.8.
Measures
Study surveys are available online at www.unc.edu/~ntbrewer/hpv.htm.
Parent survey—The parent survey included the six brief motivational messages, plus nine 
longer messages (17), for a total of fifteen messages. Parents were randomly assigned to 
panels (Panel A, Panel B, Panel C), each of which included two brief messages and three 
longer messages in a random order. The survey asked parents, “Which of these statements 
made by a doctor would persuade you to get the HPV vaccine for [child’s name]?” Before 
viewing the messages, parents indicated the number of HPV vaccine doses their children had 
received (coded as 0 or ≥1 doses). For children who had not initiated HPV vaccination, the 
survey assessed parents’ HPV vaccination intention by asking, “How likely are you to get 
[child’s name] the HPV vaccine in the next year? Would you say you … [definitely won’t, 
probably won’t, probably will, definitely will].” The survey also evaluated attitudes towards 
adolescent vaccines, including importance of HPV vaccine: “I feel that the HPV vaccine for 
[child’s name] is … [not important, slightly important, moderately important, very 
important, extremely important].” On demographic and household characteristics, the survey 
assessed respondents’ sex, age, race/ethnicity, education, marital status, household income, 
and state of residence. It also assessed the index child’s sex and age.
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Physician survey—The physician survey included the six brief motivational messages 
presented to parents and asked, “Which of these statements would you use to persuade 
parents to get HPV vaccine for their 11–12 year olds?” Physicians could choose as many 
messages that applied or select none of these. On demographic and professional 
characteristics, our survey assessed respondents’ medical specialty, sex, and number of years 
in practice since residency. Respondents also indicated their typical adolescent patient 
volume per week and the percentage of vaccine doses they administer that are provided by 
the federal Vaccines for Children (VFC) program. On clinical practice characteristics, 
respondents reported their practice type and the total number of physicians in the clinic. 
Respondents also reported the state in which their clinic is located, which we categorized 
these locations into one of four US census regions.
Data analysis
We calculated frequencies and percentages of respondents who indicated that a given 
message would persuade them (parents) or that they would use a given message to persuade 
parents (physicians) to get HPV vaccine for their child. For parent data, we used bivariate 
logistic regression models to determine if message endorsement differed by child’s HPV 
vaccination status. Among parents whose child was not previously vaccinated, we conducted 
bivariate logistic regression models to assess whether message endorsement differed by 
HPV vaccine intention. For all parents, we used bivariate logistic regression to identify 
correlates of endorsement of each motivational message. Candidate correlates were child’s 
HPV vaccination status, parent’s intention to vaccinate their child, parent’s race/ethnicity, 
parent’s education level, child’s age, child’s sex, and parents’ perception of HPV vaccine 
importance. The parent Panels A, B, and C were similar on 10 of 11 demographic variables, 
indicating that randomization successfully created largely equivalent groups; as the panels 
differed on income (p = .05), analyses controlled for income. Given that message 
endorsement differed by child’s vaccination status, analyses also controlled for this variable. 
For physician data, we used chi-square tests to identify correlates of endorsement of each 
motivational message. Candidate correlates were medical specialty and years in practice. We 
conducted analyses using SAS Version 9.4 (Cary, NC). Statistical tests were two-tailed with 
a critical alpha of 0.05.
RESULTS
Sample characteristics
Parents—About half of parents were female (56%) (Table 1). About 9% of parents were 
non-Hispanic Black and 14% were Hispanic. Nearly two-thirds (62%) had at least some 
college education. Almost half (47%) reported an annual household income of $75,000 or 
more and the majority (84%) lived in a metropolitan area. About one-quarter (28%) 
responded with regard to an 11- or 12-year-old child. About half (51%) of parents reported 
their index child was male and just over half (54%) reported their child had not received any 
doses of HPV vaccine.
Physicians—Just over half of respondents were pediatricians (53%), roughly two-thirds 
(68%) were male, and over half (55%) had been practicing for 20 or more years. The largest 
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proportion saw 10–24 adolescent patients weekly (45%). Most respondents worked in 
private practices (85%), and about half (51%) reported that their practice had four or fewer 
physicians.
Parents’ endorsement of messages
Parents’ endorsement of message persuasiveness averaged 41% (range: 9%–65%) for brief 
messages and 60% (range: 42%–70%) for longer messages (Table 2). At least half of parents 
supported 8 of the 9 longer messages and 3 of 6 brief messages. About 18% of parents 
endorsed all messages they read, whereas 22% did not endorse any.
Among the brief messages, the highest proportion of parents endorsed a message that 
explicitly expressed a strong recommendation for HPV vaccine (B5 important cancer 
prevention vaccine; 65%) (Figure 1). Many parents also supported messages that speak 
directly to their role in preventing their child from getting anal/cervical cancer through HPV 
vaccination (B3 prevent cancer; 59%) and messages that emphasize their control over 
whether their child becomes infected with HPV (B4 control getting HPV; 58%). For the 
longer, CDC-developed messages, the highest proportion of parents supported a message 
with information about HPV vaccine effectiveness shown in clinical trials and studies in the 
US and other countries (L8 effective vaccine; 70%) (Table 2). About two-thirds of parents 
also endorsed messages about the prevalence of HPV infection and the cancers and 
precancerous conditions HPV vaccine protects against (L7 HPV causes cancers; 67%), 
messages about vaccine safety and an emphasis on minor, short-term side effects (L2 safe 
vaccine; 65%), and a longer version of the brief message in which a physician clearly gives a 
strong recommendation for HPV vaccine (L6 important cancer prevention vaccine; 65%).
HPV vaccination status—Endorsement of each of the 15 messages was higher among 
parents whose children had received HPV vaccine (all p <.05) (Table 2). Parents whose 
children had not received any doses of HPV vaccine favored five longer messages (L2 safe 
vaccine, L5 HPV is common, L6 important cancer prevention vaccine, L7 HPV causes 
cancers, and L8 effective vaccine; 53%–56%) and three short messages (B3 prevent cancer, 
B4 control getting HPV, and B5 important cancer prevention vaccine; 48%–49%). Few 
parents of unvaccinated children endorsed brief messages B6 (5%), which uses a car seatbelt 
analogy, and B1 (16%), in which a physician draws on the experience of vaccinating his or 
her own child. About two-thirds (67%) of parents of unvaccinated children supported at least 
one message, as did 91% of parents whose child received ≥1 dose of HPV vaccine.
In an exploratory analysis, we examined sociodemographic correlates of not endorsing any 
messages among parents of an unvaccinated child. In bivariate logistic regression analyses, 
we identified parent race and marital status as significant predictors of not endorsing any 
messages. In a multivariable model containing these two predictor variables, parents who 
reported Black, non-Hispanic race had lower odds of not endorsing any messages compared 
to White, non-Hispanic parents (odds ratio [OR], 0.47; 95% confidence interval [CI], 0.24–
0.92). Parents who reported they were not married had lower odds of not endorsing any 
messages compared to parents who were married (OR, 0.58; 95% CI; 0.37–0.89).
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HPV vaccination intentions—For 14 of the 15 messages, parents with higher prior 
intentions to vaccinate were more likely to say the messages would be persuasive (all p < .
001) (Supplementary Table S2; Figure 2). Of parents who probably would not get their child 
vaccinated, more than 60% endorsed three longer messages (L5 HPV is common, L7 HPV 
causes cancers, L8 effective vaccine; 61%–64%). About half endorsed three brief messages 
(B3 prevent cancer, B4 control getting HPV, and B5 important cancer prevention vaccine; 
48%–51%). Of parents who definitely would not get their child vaccinated, about one-
quarter indicated three brief messages would persuade them to vaccinate their child (B3 
prevent cancer, B4 control getting HPV, and B5 important cancer prevention vaccine; 23%–
25%). Two longer messages would be effective with about one-quarter of these parents (L5 
HPV is common and L8 effective vaccine; 23%–24%). About one-third (33%) of parents 
who definitely would not get their child vaccinated and 75% of parents who probably would 
not get their child vaccinated endorsed at least one message (Figure 3).
Demographics—Endorsement was not associated with parent race/ethnicity, parent 
education, child age, or child sex (all p >.05; Supplementary Table S3).
Physicians’ endorsement of messages
Physicians’ endorsement of the brief messages averaged 39%; about 4% of physicians 
endorsed all messages, whereas 7% did not endorse any messages. Of the six brief messages 
presented to physicians, the highest proportion of physicians endorsed B5 (important cancer 
prevention vaccine, 69%), closely followed by B3 (prevent cancer, 64%) (Figure 1). The 
lowest proportion of physicians (9%) reported they would use message B6 (seatbelt analogy) 
to persuade parents to agree to HPV vaccine.
Compared to pediatricians, a higher proportion of family physicians endorsed message B3 
(prevent cancer, 59% vs. 69%, p = .002), but a lower proportion of family physicians 
endorsed messages B1 (physician vaccinates own child, 35% vs. 25%, p = .003) and B5 
(important cancer prevention vaccine, 74% vs. 63%, p < .001). Relative to clinicians who 
have been in practice for ≤19 years, a higher proportion of those practicing longer endorsed 
messages B1 (physician vaccinates own child, 24% vs. 36%, p < .001) and B4 (control 
getting HPV, 32% vs. 41%, p = .019). No other associations were statistically significant (all 
p > .05).
DISCUSSION
Through our national survey of parents, we identified three brief (B3–B5) and eight longer 
(L1–L3, L5–L9) messages that at least half of parents reported would persuade them to 
agree to HPV vaccination for their children. Physicians also endorsed two of these brief 
messages touching on the strong belief “in the importance of this cancer-preventing vaccine” 
(B5) and that the child could get cancer as an adult “but you can stop that right now” (B3). 
Given the importance of provider recommendation in HPV vaccine uptake (7, 27), perhaps it 
is not surprising that a high proportion of parents endorsed a straightforward and strong 
recommendation for HPV vaccine. Equally high proportions of parents endorsed the brief 
and longer versions of this message, suggesting that such a recommendation need not be 
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lengthy so long as the physician clearly states that he or she strongly recommends HPV 
vaccine.
Many parents also endorsed messages that included information about vaccine safety and 
effectiveness (L2, L8), the importance of vaccinating prior to sexual activity (L3), HPV 
infection being common (L5), and cancer prevention (L1, L6, L7, L9). These messages 
address the primary parental barriers to HPV vaccination, including concerns about vaccine 
safety, lack of knowledge, and belief that HPV vaccine is not needed or not necessary (7). 
Moreover, the messages align with communication best practices that suggest effective 
messages highlight HPV vaccine’s role in cancer prevention, explain risks and prevalence of 
HPV infection, and provide evidence about HPV vaccine safety (28).
These messages may be especially useful as part of a larger HPV vaccine recommendation 
strategy. The survey used in the current study informed an intervention in which we 
developed and led a training that taught clinicians an HPV vaccine recommendation strategy. 
As part of the strategy, we trained clinicians on an approach for eliciting and easing parents’ 
primary concern about HPV vaccine, and to end with a strong recommendation. In the 
context of this strategy, we foresee physicians using the messages from the current study 
during these steps. These messages may be particularly helpful once physicians have 
identified a focal point for discussion by eliciting parents’ primary concern about HPV 
vaccine. To support their communication with parents, physicians can use the motivational 
message that best addresses the parent’s specific concern. Also, physicians can use a 
message to end the discussion with a strong recommendation for HPV vaccine (e.g., B5 
important cancer prevention vaccine). Given that we did not identify a difference in parental 
endorsement of messages across demographic subgroups, physicians may be able to 
effectively use these messages across demographic subgroups.
Of particular interest, some parents without prior intentions to vaccinate their child identified 
messages that would be persuasive. Two messages that were the most highly endorsed by 
these parents placed the onus of protection on the parent (B3) and emphasized the control 
they possess over their child’s health (B4). This finding is aligned with the tenets of various 
theories of fear appeals, which posit that fear messages inspire action if the receiver believes 
he or she has some control over the situation (29). Parents without prior intentions to 
vaccinate their child may be particularly receptive to messages that arouse fear while 
fostering a sense of efficacy. Our findings offer promise for appealing to parents with a 
range of prior intentions to vaccinate.
Concordance between parents’ and physicians’ perceptions of the brief messages was fairly 
high. One exception was message B4 (control getting HPV), where many parents (58%) 
reported the message was persuasive, yet only 37% of physicians would use this message to 
persuade parents. It is especially concerning that so few physicians would use this message 
given that it was one of the top messages that would persuade parents without prior 
intentions to vaccinate their child. It is unclear whether physicians were not amenable to 
using this message because they personally do not believe in its content, or because they do 
not think the message would motivate parents.
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We also identified some differences in message endorsement by physician specialty and 
length of time in practice. Pediatricians typically are stronger proponents of vaccination 
compared to other physician specialties, including family physicians (30, 31). Thus, it may 
be unsurprising that pediatricians preferred messages B1 (physician vaccinates own child) 
and B5 (important cancer prevention vaccine), both of which reflected personal endorsement 
and experience, whereas family physicians preferred message B3 (prevent cancer), which 
does not use language that reflects their personal beliefs. Given that so many parents 
reported message B5 (important cancer prevention vaccine) would persuade them to pursue 
HPV vaccination, it would be worthwhile to encourage family physicians to use this 
message or further explore their hesitancy to use it. Using this message could be easily 
incorporated into routine clinical practice and included in training materials targeted to 
helping family physicians make effective HPV vaccine recommendations.
To facilitate comprehension, experts recommend that health information be written at a sixth 
grade or lower reading level (32, 33). We found that the brief messages were generally 
around this recommended grade level whereas the longer messages were around four grades 
above the recommended level. CDC has since disseminated a new set of messages for 
physicians to use to address parents’ questions about HPV vaccine that are somewhat shorter 
than the previous CDC messages but still lengthy (38 vs 52 words) (34). Grade level of the 
new messages remained high and unchanged at around tenth grade. Given that the messages 
are designed for physicians to deliver to parents orally, it is worthwhile for future research to 
explore parents’ comprehension of the messages when spoken by a physician. Also of note, 
the highest proportion of parents endorsed the brief statement (B5 important cancer 
prevention vaccine) with the highest reading grade level (10), and over half of parents 
endorsed most of the longer statements, with grade levels ranging from 7 to 12. Future 
research also is needed to understand the trade-offs between message reading grade level, 
persuasiveness, message length, and ability for providers and patients to remember the 
messages.
Study strengths include data from large, national samples of parents and primary care 
physicians, including physicians who practice in specialties that deliver the majority of HPV 
vaccine doses in the US (10). To our knowledge, our study is among the first to evaluate the 
messages developed and disseminated by the CDC. Study weaknesses include that we 
achieved a modest cooperation rate for the physician survey, which is a common challenge 
for physician surveys (35). The study relied on parents’ and physicians’ self-report in 
response to hypothetical scenarios; thus, we were unable to account for clinical context or 
other factors that may affect physicians’ use of and parents’ receptivity to the messages. For 
instance, physicians’ non-verbal cues may influence parents’ perceptions of message 
persuasiveness. Also, it is possible that physicians will modify the messages rather than say 
them verbatim; these modifications may enhance or undermine the messages’ 
persuasiveness. Moreover, we did not clarify with parents whether they were motivated by 
the message in its entirety or if there was a specific component of the message that was 
particularly stimulating. These limitations highlight that this research should be augmented 
with future studies that further test these messages. Future research also should extend this 
work by examining whether these messages lead to HPV vaccine uptake. Furthermore, 
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future work should distinguish between messages designed to address parent concerns and 
messages intended to direct parents to vaccinate.
Conclusion
Our national study of parents and physicians identified messages perceived as persuasive for 
motivating HPV vaccination, even among parents disinclined to vaccinate their children. The 
lack of difference across demographic subgroups in parental endorsement of messages may 
suggest that these messages can be used across demographic subgroups, and warrants further 
investigation. Our findings provide physicians with evidence that using these messages may 
help them to communicate effectively with parents about this important cancer-preventing 
vaccine.
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Figure 1. 
Physicians’ (n = 776) and parents’ (n = 1,504) belief that brief messages would encourage 
HPV vaccine uptake. Note. Panel A parents (n = 515) evaluated messages B1 and B2, Panel 
B parents (n = 483) evaluated messages B3 and B4, and Panel C parents (n = 506) evaluated 
messages B5 and B6.
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Figure 2. 
Parents’ perception of messages by HPV vaccine intention, among those whose child was 
not previously vaccinated (n = 809). Note. Brief messages are denoted by dotted lines to 
show how they perform compared to the longer messages.
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Figure 3. 
Number of messages endorsed by parents, by intention to get HPV vaccine for their child (n 
= 809).
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Table 1
Sample characteristics.
n (%)
Parent sample, n = 1504
Panel
  Panel A 515 (34)
  Panel B 483 (32)
  Panel C 506 (34)
Parent characteristics
  Sex
   Male 668 (44)
   Female 836 (56)
  Age (y)
   21–29 34 (2)
   30–44 809 (54)
   45–59 617 (41)
   ≥60 44 (3)
  Race
   White, non-Hispanic 1058 (70)
   Black, non-Hispanic 135 (9)
   Other, non-Hispanicb 99 (7)
   Hispanic 212 (14)
  Education
   High school degree or less 576 (38)
   Some college, no degree 390 (26)
   Bachelor’s degree or higher 538 (36)
  Marital status
   Married 1207 (80)
   Not married 297 (20)
Household characteristics
  Income
   <$35K 329 (22)
   $35K – <$75K 470 (31)
   ≥$75K 705 (47)
  MSA status
   Non-metropolitan 236 (16)
   Metropolitan 1268 (84)
  Region
   Northeast 261 (17)
   Midwest 393 (26)
   South 499 (33)
   West 351 (23)
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n (%)
Child characteristics
  Sex
   Male 765 (51)
   Female 739 (49)
  Age (y)
   11–12 422 (28)
   13–14 443 (29)
   15–17 639 (42)
  HPV vaccination status
   0 doses 809 (54)
   ≥1 doses 695 (46)
Physician sample, n = 776
Personal characteristics
  Medical specialty
   Pediatrics 410 (53)
   Family practice 366 (47)
  Sex
   Male 526 (68)
   Female 250 (32)
  Years in practice
   ≤19 352 (45)
   ≥20 424 (55)
  Adolescent patients seen in typical week
   ≤9 129 (17)
   10–24 351 (45)
   ≥25 296 (38)
  Vaccine doses through VFC
   ≤9% 290 (37)
   10%–49% 274 (35)
   ≥50% 152 (20)
   Not sure 60 (8)
Clinic or practice characteristics
  Type
   Private practice (solo, group, HMO) 660 (85)
   Othera 116 (15)
  Total physicians
   1–4 398 (51)
   5–9 217 (28)
   ≥10 161 (21)
  Region
   Northeast 184 (24)
   Midwest 165 (21)
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n (%)
   South 275 (35)
   West 152 (20)
Note. Percentages may not total 100% due to rounding. HMO: health maintenance organization. HPV: human papillomavirus. MSA: metropolitan 
statistical area. VFC: Vaccines for Children program.
a
Includes hospital- and university-based clinics, Federally Qualified Health Centers, and community, rural, migrant, Indian, military, public health, 
and school health clinics.
b
Includes 39 participants who reported two or more races, non-Hispanic.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Malo et al. Page 19
Ta
bl
e 
2
Pa
re
n
ts
’ p
er
ce
pt
io
ns
 o
f w
he
th
er
 m
es
sa
ge
s t
o 
pr
om
ot
e 
H
PV
 v
ac
ci
na
tio
n 
ar
e 
pe
rs
ua
siv
e,
 b
y 
ch
ild
’s
 H
PV
 v
ac
ci
na
tio
n 
sta
tu
s (
n
 
=
 1
50
4).
M
es
sa
ge
C
hi
ld
’s
 H
PV
 V
a
cc
in
at
io
n 
St
at
us
To
ta
l
0 
do
se
s
≥1
 d
os
e
n
(%
)
n
(%
)
n
(%
)
p
Pa
n
el
 A
n
 
=
 5
15
n
 
=
 2
79
n
 
=
 2
36
B
1.
M
y 
ch
ild
 h
as
 g
ot
te
n 
H
PV
 v
ac
ci
ne
. [
Ch
ild
’s 
na
me
] s
ho
uld
, to
o. 
(br
ief
)
12
5
(24
)
 
 
46
(16
)
 
 
79
(33
)
<
.0
01
*
*
B
2.
I s
ee
 y
ou
 g
ot
 h
ep
at
iti
s B
 v
ac
ci
ne
 fo
r [
ch
ild
’s 
na
me
]. 
Th
at’
s a
lso
 a 
ca
nc
er 
va
cc
in
e 
fo
r a
n 
in
fe
ct
io
us
 d
ise
as
e.
 (b
rie
f)
17
1
(33
)
 
 
80
(29
)
 
 
91
(39
)
 
 
.
01
8*
L1
.
H
PV
 v
ac
ci
ne
 is
 v
er
y 
im
po
rta
nt
 b
ec
au
se
 it
 p
re
v
en
ts
 c
an
ce
r. 
I w
an
t [
ch
ild
’s 
na
me
] t
o b
e p
ro
tec
ted
 fr
om
 ca
nc
er.
 
Th
at
’s
 w
hy
 I’
m
 
re
co
m
m
en
di
ng
 th
at
 [h
e/s
he
] r
ec
eiv
es
 th
e 
fir
st 
do
se
 o
f H
PV
 v
ac
ci
ne
 to
da
y. 
(lo
ng
er)
29
3
(57
)
12
6
(45
)
16
7
(71
)
<
.0
01
*
*
L2
.
H
PV
 v
ac
ci
ne
 h
as
 b
ee
n 
ca
re
fu
lly
 st
ud
ie
d 
by
 m
ed
ic
al
 a
nd
 sc
ie
nt
ifi
c 
ex
pe
rts
. H
PV
 v
ac
ci
ne
 h
as
 b
ee
n 
sh
ow
n
 to
 b
e 
ve
ry
 e
ffe
ct
iv
e 
an
d 
v
er
y 
sa
fe
. L
ik
e 
o
th
er
 sh
ot
s, 
m
os
t s
id
e 
ef
fe
ct
s a
re
 m
ild
, p
rim
ar
ily
 p
ai
n 
or
 re
dn
es
s i
n 
th
e 
ar
m
. T
hi
s s
ho
ul
d 
go
 aw
ay
 q
ui
ck
ly
,
 
an
d 
H
PV
 
v
ac
ci
ne
 h
as
 n
ot
 b
ee
n 
as
so
ci
at
ed
 w
ith
 a
ny
 lo
ng
-te
rm
 si
de
 e
ffe
ct
s. 
Si
nc
e 
20
06
, a
bo
ut
 5
7 
m
ill
io
n 
do
se
s o
f H
PV
 v
ac
ci
ne
 h
av
e 
be
en
 
di
str
ib
u
te
d 
in
 th
e 
U
.S
., 
an
d 
in
 th
e 
ye
ar
s o
f H
PV
 v
ac
ci
ne
 sa
fe
ty
 st
ud
ie
s a
nd
 m
on
ito
rin
g,
 n
o 
se
rio
us
 sa
fe
ty
 c
on
ce
rn
s h
av
e 
be
en
 
id
en
tif
ie
d.
 (lo
ng
er)
33
3
(65
)
15
1
(54
)
18
2
(77
)
<
.0
01
*
*
L3
.
W
e’
re
 v
ac
ci
na
tin
g 
to
da
y 
so
 [c
hil
d’
s n
am
e] 
wi
ll h
av
e 
th
e 
be
st 
pr
ot
ec
tio
n 
po
ss
ib
le
 lo
ng
 b
ef
or
e 
th
e 
sta
rt 
of
 a
ny
 k
in
d 
of
 se
x
u
al
 a
ct
iv
ity
.
 
W
e 
v
ac
ci
na
te
 p
eo
pl
e 
w
el
l b
ef
or
e 
th
ey
 a
re
 e
x
po
se
d 
to
 a
n 
in
fe
ct
io
n,
 a
s i
s t
he
 c
as
e 
w
ith
 m
ea
sle
s a
nd
 th
e 
ot
he
r r
ec
om
m
en
de
d 
ch
ild
ho
od
 
v
ac
ci
ne
s. 
Si
m
ila
rly
,
 
w
e 
w
an
t t
o 
va
cc
in
at
e 
ch
ild
re
n 
w
el
l b
ef
or
e 
th
ey
 g
et
 e
x
po
se
d 
to
 H
PV
.
 
(lo
ng
er)
30
3
(59
)
13
4
(48
)
16
9
(72
)
<
.0
01
*
*
Pa
n
el
 B
n
 
=
 4
83
n
 
=
 2
65
n
 
=
 2
18
B
3.
[C
hil
d’
s n
am
e] 
ca
n g
et 
[an
al/
ce
rv
ica
l c
an
ce
r] 
as
 an
 ad
ult
, b
u
t y
ou
 c
an
 st
op
 th
at
 ri
gh
t n
ow
.
 
Th
e 
H
PV
 v
ac
ci
ne
 p
re
v
en
ts
 m
os
t [
an
al/
ce
rv
ic
al
 c
an
ce
rs
]. 
(br
ief
)
28
5
(59
)
13
1
(49
)
15
4
(71
)
<
.0
01
*
*
B
4.
Th
er
e 
w
ill
 b
e 
m
an
y 
th
in
gs
 in
 [c
hil
d’
s n
am
e]’
s l
ife
 th
at 
yo
u c
an
’t 
co
ntr
ol.
 B
ut 
yo
u c
an
 co
ntr
ol 
wh
eth
er 
[h
e/s
he
] g
ets
 so
me
 da
ng
ero
us
 
ki
nd
s o
f H
PV
.
 
(br
ief
)
28
1
(58
)
12
8
(48
)
15
3
(70
)
<
.0
01
*
*
L4
.
R
es
ea
rc
h 
ha
s s
ho
w
n
 th
at
 g
et
tin
g 
th
e 
H
PV
 v
ac
ci
ne
 d
oe
s n
ot
 m
ak
e 
ki
ds
 m
or
e 
lik
el
y 
to
 b
e 
se
x
u
al
ly
 a
ct
iv
e 
o
r 
st
ar
t h
av
in
g 
se
x
 a
t a
 
yo
un
ge
r a
ge
. (l
on
ge
r)
20
3
(42
)
 
 
81
(31
)
12
2
(56
)
<
.0
01
*
*
L5
.
H
PV
 is
 so
 c
om
m
on
 th
at
 a
lm
os
t e
v
er
yo
ne
 w
ill
 b
e 
in
fe
ct
ed
 a
t s
om
e 
po
in
t. 
It 
is 
es
tim
at
ed
 th
at
 7
9 
m
ill
io
n 
A
m
er
ic
an
s a
re
 cu
rre
nt
ly
 
in
fe
ct
ed
, w
ith
 1
4 
m
ill
io
n 
ne
w
 H
PV
 in
fe
ct
io
ns
 e
ac
h 
ye
ar
.
 
M
os
t p
eo
pl
e 
in
fe
ct
ed
 w
ill
 n
ev
er
 k
no
w
.
 
So
 ev
en
 if
 [c
hil
d’
s n
am
e] 
wa
its
 u
nt
il 
m
ar
ria
ge
 to
 h
av
e 
se
x
, 
o
r 
o
n
ly
 h
as
 o
ne
 p
ar
tn
er
 in
 th
e 
fu
tu
re
, [
he
/sh
e] 
co
uld
 st
ill
 be
 ex
po
se
d 
if 
[h
is/
he
r] 
pa
rtn
er 
ha
s b
ee
n e
x
po
se
d.
 
(lo
ng
er)
29
7
(61
)
14
4
(54
)
15
3
(70
)
<
.0
01
*
*
L6
.
I s
tro
ng
ly
 b
el
ie
v
e 
in
 th
e 
im
po
rta
nc
e 
of
 th
is 
ca
nc
er
-
pr
ev
en
tin
g 
va
cc
in
e,
 a
nd
 I 
ha
v
e 
gi
v
en
 H
PV
 v
ac
ci
ne
 to
 m
y 
ch
ild
. E
xp
er
ts 
(li
ke
 th
e 
A
m
er
ic
an
 A
ca
de
m
y 
of
 P
ed
ia
tri
cs
, c
an
ce
r d
oc
to
rs
, a
nd
 th
e 
CD
C)
 al
so
 ag
ree
 th
at 
thi
s v
ac
ci
ne
 is
 v
er
y 
im
po
rta
nt
 fo
r [
ch
ild
’s 
na
me
]. 
(lo
ng
er)
31
6
(65
)
14
0
(53
)
17
6
(81
)
<
.0
01
*
*
Pa
n
el
 C
n
 
=
 5
06
n
 
=
 2
65
n
 
=
 2
41
B
5.
I s
tro
ng
ly
 b
el
ie
v
e 
in
 th
e 
im
po
rta
nc
e 
of
 th
is 
ca
nc
er
-
pr
ev
en
tin
g 
va
cc
in
e 
fo
r [
ch
ild
’s 
na
me
]. 
(br
ief
)
32
9
(65
)
13
0
(49
)
19
9
(83
)
<
.0
01
*
*
B
6.
W
o
u
ld
 y
ou
 w
ai
t u
nt
il 
[ch
ild
’s 
na
me
] i
s i
n a
 ca
r a
cc
ide
nt 
be
fo
re 
yo
u t
ell
 [h
im
/he
r] 
to 
we
ar 
a s
ea
tbe
lt?
 (b
rie
f)
 
 
46
(9)
 
 
14
(5)
 
 
32
(13
)
.
00
1*
*
L7
.
H
PV
 c
an
 c
au
se
 c
an
ce
rs
 o
f t
he
 c
er
vi
x,
 v
ag
in
a,
 a
nd
 v
ul
va
 in
 w
o
m
en
, 
ca
n
ce
r 
o
f t
he
 p
en
is 
in
 m
en
, a
nd
 c
an
ce
rs
 o
f t
he
 a
nu
s a
nd
 th
e 
m
o
u
th
 o
r t
hr
oa
t i
n 
bo
th
 w
o
m
en
 a
n
d 
m
en
. T
he
re
 a
re
 a
bo
ut
 2
6,
00
0 
of
 th
es
e c
an
ce
rs
 ea
ch
 y
ea
r—
an
d 
m
os
t c
ou
ld
 b
e p
re
v
en
te
d 
w
ith
 
H
PV
 v
ac
ci
ne
. T
he
re
 a
re
 a
lso
 m
an
y 
m
or
e 
pr
ec
an
ce
ro
us
 c
on
di
tio
ns
 re
qu
iri
ng
 tr
ea
tm
en
t t
ha
t c
an
 h
av
e 
la
sti
ng
 e
ffe
ct
s. 
(lo
ng
er)
33
8
(67
)
14
9
(56
)
18
9
(78
)
<
.0
01
*
*
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Malo et al. Page 20
M
es
sa
ge
C
hi
ld
’s
 H
PV
 V
a
cc
in
at
io
n 
St
at
us
To
ta
l
0 
do
se
s
≥1
 d
os
e
n
(%
)
n
(%
)
n
(%
)
p
L8
.
In
 c
lin
ic
al
 tr
ia
ls 
of
 b
oy
s a
nd
 g
irl
s, 
th
e 
va
cc
in
e 
w
as
 s
ho
w
n
 to
 b
e 
ex
tr
em
el
y 
ef
fe
ct
iv
e.
 In
 a
dd
iti
on
, s
tu
di
es
 in
 th
e 
U
.S
. a
nd
 o
th
er
 
co
u
n
tr
ie
s t
ha
t h
av
e 
in
tro
du
ce
d 
H
PV
 v
ac
ci
ne
 h
av
e 
sh
ow
n
 a
 s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 in
fe
ct
io
ns
 c
au
se
d 
by
 th
e 
H
PV
 ty
pe
s t
ar
ge
te
d 
by
 
th
e 
va
cc
in
e.
 (lo
ng
er)
35
2
(70
)
14
9
(56
)
20
3
(84
)
<
.0
01
*
*
L9
.
I w
an
t t
o 
m
ak
e 
su
re
 th
at
 [c
hil
d’
s n
am
e] 
rec
eiv
es
 a
ll 
3 
sh
ot
s o
f H
PV
 v
ac
ci
ne
 to
 g
iv
e 
[h
im
/he
r] 
the
 be
st 
po
ssi
ble
 pr
ote
cti
on
 fr
om
 
ca
n
ce
r 
ca
u
se
d 
by
 H
PV
.
 
Pl
ea
se
 m
ak
e 
su
re
 to
 m
ak
e 
ap
po
in
tm
en
ts 
on
 th
e 
w
ay
 o
ut
, a
nd
 p
ut
 th
os
e 
ap
po
in
tm
en
ts 
on
 y
ou
r c
al
en
da
r b
ef
or
e 
yo
u 
le
av
e 
th
e 
of
fic
e 
to
da
y!
 (lo
ng
er)
28
5
(56
)
10
4
(39
)
18
1
(75
)
<
.0
01
*
*
N
ot
e. 
Th
e 
m
es
sa
ge
 le
ng
th
 is
 in
di
ca
te
d 
in
 p
ar
en
th
es
es
. B
rie
f m
es
sa
ge
s c
on
sis
te
d 
of
 2
5 
or
 fe
w
er
 w
o
rd
s, 
w
he
re
as
 lo
ng
er
 m
es
sa
ge
s h
ad
 m
or
e 
th
an
 2
5 
w
o
rd
s. 
Fr
eq
ue
nc
ie
s a
nd
 p
er
ce
nt
ag
es
 re
fle
ct
 a
gr
ee
m
en
t t
ha
t 
th
e 
m
es
sa
ge
 w
o
u
ld
 b
e 
pe
rs
ua
siv
e.
 P
 
v
al
ue
s w
er
e 
de
riv
ed
 fr
om
 b
iv
ar
ia
te
 lo
gi
sti
c 
re
gr
es
sio
n 
m
od
el
s t
ha
t d
et
er
m
in
ed
 if
 e
nd
or
se
m
en
t o
f e
ac
h 
m
es
sa
ge
 d
iff
er
ed
 b
y 
ch
ild
’s
 H
PV
 v
ac
ci
na
tio
n 
sta
tu
s.
*
p 
<
 .0
5
*
*
p 
<
 .0
1
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